

From: [Grande-McNeill, Geneva](#)
To: [Panchuk, Sarah](#); [gerlo@telus.net](#); [mwalden@henleywalden.com](#); [alan.blair@gowlings.com](#); [Barron.Carswell@gov.bc.ca](#); [boris.tyzuk@gov.bc.ca](#); [cbuchanan@labourlawoffice.com](#); [cwatson@maclaw.bc.ca](#); [davidmrobbins@woodwardandcompany.com](#); [james_hickling@aboriginal-law.com](#); [Jharrison@ecojustice.ca](#); [jhunter@litigationchambers.com](#); [keithlowes@shaw.ca](#); [krobertson@jfklaw.ca](#); [leah@mandellpinder.com](#); [lglowacki@ratcliff.com](#); [donrosenbloom@shaw.ca](#); [Timberg, Tim](#); [bcfish@shawlink.ca](#); [dwb@bht.com](#); [syee@arvayfinlay.com](#); [tdickson@farris.com](#); [Clifton.Prowse@gov.bc.ca](#); [lisa@ngariss.org](#); [Katrina@ethoslaw.ca](#); [Lunn, John](#); [Brock Martland](#); [Grant, Kathy](#); [Chan, Jennifer](#)
Cc: [Taylor, Mitch](#); [East, Mark](#); [Grande-McNeill, Geneva](#); [Chen, Helen](#)
Subject: Cohen - Exh 2126
Date: Monday, December 19, 2011 12:27:44 PM
Attachments: [AquaPIQ re Dr. Kristie Miller tests for ISA PAGE 5.pdf](#)

Further to counsel speaking in hearing this morning, below and attached is an explanation why Exhibit 2126 cannot be printed with the full text in the call log box, along with the full text.

Regarding page 5 of Exhibit 2126 – cut off text

CFIA is not able to print off a clean copy of the page without the text being cut off. The program used to generate these forms is old and the information is designed to link to their database. Text sometimes gets cut off when they print the forms to PDF or to paper. CFIA has provided a print screen of the form (attached) and the text is also below.

"While conducting genomic fish research, Dr Kristie Miller identified 3 signatures she considered typical of viral impact. At first Dr Miller looked for a parvovirus, but after her 25th August 2011, disclosure at the Cohen Commission, she decided to re-test her samples using RT PCR, for both IHN & ISAV, with negative results.

Following Dr Fred Kibenge's lab report to Professor Routledge, on October 17th 2011, with presumptive findings of ISAV, Dr Miller thought her tests may have not detected ISAV because she tested for segment 6. Therefore Dr Miller conducted 5 different assays on samples from these smolts, for ISAV, using similar primer sets, as those used by Dr Fred Kibenge. At this time she looked for various viral segments.

Kim Klotins spoke with Dr. Kyle Garver on December 6, 2011 and he provided the following information: initially Dr. Miller conducted an assay for segment 8 and found some positives (no controls were used).

Dr. Garver evaluated the provided amplification plot and her sequencing data (she indicated that the primers she used were OIE primers but did not provide the primers to Dr. Garver upon request) and he did not consider the findings to indicate a suspicion of ISAV but agreed to test her most positive and some negative samples using NAAHLS primers for ISAV (in a blinded fashion). The results were negative. In the meantime, Dr. Miller continued development of assays for other genomic segments of ISAV, including segment 7, and continued to record positive findings. She was told by Dr. Garver to notify her suspicion to the CFIA and send some of her samples to the National

Reference Laboratory for ISAV in Moncton (blinded samples were sent on November 29, 2011). I requested that they be sent using the NAAHP Laboratory Submission Form."

<<AquaPIQ re Dr Kristie Miller tests for ISA_PAGE 5.pdf>>

Geneva Grande-McNeill
Counsel

Department of Justice Canada
British Columbia Regional Office
900 - 840 Howe Street
Vancouver, B.C. V6Z 2S9

geneva.grande-mcneill@justice.gc.ca

Telephone: 604-775-7555

Government of Canada

The information transmitted in or attached to this email is intended only for the person(s) or entity(ies) to which it is addressed and may contain confidential and privileged information and/or material, including information and/or material subject of one or both of solicitor-client privilege and litigation privilege. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon this information and/or material by persons or entities other than the intended recipient is prohibited. If you receive this in error, please contact the sender and delete the material from any computer.

Informed Desktop eForms - [CFIA_ACIA_#3115616-v1-AQAH-DDC-MN-064609_ISAV_Kristi_Miller_PBS_IFM]

File Edit Cell Database List View Window Help

Work Page | Call Log | A1.1 | A1.2 | A1.2 cont. & A1.3 | A1.3 cont. & A1.4 | A2 | A2 cont. & A3 | A3 cont. | B1 & B1.1 | B1.2 & B1.3 | B1.3 & C1 & C2 | C3 | C3 cont. & C4 | C5,C6,C7,C8 | D1,D2 | D3,D4 | Contact Information | Cor

Other Available History / Autres données disponibles

While conducting genomic fish research, Dr Kristie Miller identified 3 signatures she considered typical of viral impact. At first Dr Miller looked for a parvovirus, but after her 25th August 2011, disclosure at the Cohen Commission, she decided to re-test her samples using RT PCR, for both IHN & ISAV, with negative results.

Following Dr Fred Kibenge's lab report to Professor Routledge, on October 17th 2011, with presumptive findings of ISAV, Dr Miller thought her tests may have not detected ISAV because she tested for segment 6. Therefore Dr Miller conducted 5 different assays on samples from these smolts, for ISAV, using similar primer sets, as those used by Dr Fred Kibenge. At this time she looked for various viral segments.

Kim Klotins spoke with Dr. Kyle Garver on December 6, 2011 and he provided the following information: initially Dr. Miller conducted an assay for segment 8 and found some positives (no controls were used). Dr. Garver evaluated the provided amplication plot and her sequencing data (she indicated that the primers she used were OIE primers but did not provide the primers to Dr. Garver upon request) and he did not consider the findings to indicate a suspicion of ISAV but agreed to test her most positive and some negative samples using NAAHLS primers for ISAV (in a blinded fashion). The results were negative. In the meantime, Dr. Miller continued development of assays for other genomic segments of ISAV, including segment 7, and continued to record positive findings. She was told by Dr. Garver to notify her suspicion to the CFIA and send some of her samples to the National Reference Laboratory for ISAV in Moncton (blinded samples were sent on November 29, 2011). I requested that they be sent using the NAAHP Laboratory Submission Form.]

Fisheries and Oceans Canada Gulf Fisheries Centre 342 University Ave. Moncton N.B. E1C 9B6

Attach completed National Aquatic Animal Health Program Laboratory Submission.
Joignez le formulaire de soumission des échantillons du programme national sur la santé des animaux aquatiques complété.

If aquatic animals, gametes, carcasses, offal, or things are located on a premises, go to part [A2](#)
Note: Further contact with the premises should be with the owner or operator, not the occupier.
Si des animaux aquatiques, des gamètes, des carcasses, des abats ou des choses sont présents sur les lieux, allez à la Partie [A2](#).
Remarque : Lorsque vous devez communiquer avec l'établissement dans l'avenir, veuillez vous adresser au propriétaire ou à l'exploitant, et non à l'occupant. **A2**

If aquatic animals, gametes, carcasses, offal, or things are located in a processing plant, feed mill, or other type of plant, go to part [A3](#).
Note: Further contact with the premises should be with the owner or operator, not the occupier.
Si des animaux aquatiques, des gamètes, des carcasses, des abats ou des choses sont présents dans une usine de transformation, un provenderie ou un autre type d'établissement, allez à la Partie [A3](#).
Remarque : Lorsque vous devez communiquer avec l'établissement dans l'avenir, veuillez vous adresser au propriétaire ou à l'exploitant **A3**